What is M-FACT?
Treating itching, redness, and swelling of many skin conditions.
M-FACT lotion is a topical corticosteroid. It works by reducing inflammatory reactions and modifying immune reactions in the body.
M-FACT indications
Treatment of Allergic Rhinitis
M-FACT Nasal Spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis
M-FACT Nasal Spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Prophylaxis of Seasonal Allergic Rhinitis
M-FACT Nasal Spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older.
Treatment of Nasal Polyps
M-FACT Nasal Spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older.
How should I use M-FACT?
Use M-FACT lotion as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.
- Shake well before each use.
- Apply a small amount of M-FACT lotion to the affected area once a day. Gently rub the medicine in until it is evenly distributed. Wash your hands immediately after using M-FACT lotion, unless your hands are part of the treated area.
- If you miss a dose of M-FACT lotion, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use M-FACT lotion.
M-FACT dosage
Apply a thin film of M-FACT (M-FACT ointment) to the affected skin areas once daily. M-FACT (M-FACT ointment) may be used in pediatric patients 2 years of age or older. Since safety and efficacy of M-FACT (M-FACT ointment) have not been adequately established in pediatric patients below 2 years of age, its use in this age group is not recommended..
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Safety and efficacy of M-FACT (M-FACT ointment) in pediatric patients for more than 3 weeks have not been established.
M-FACT (M-FACT ointment) should not be used with occlusive dressings unless directed by a physician. M-FACT (M-FACT ointment) should not be applied in the diaper area if the child still requires diapers or plastic pants as these garments may constitute occlusive dressing.
How supplied
M-FACT (M-FACT ointment), 0.1%, is supplied in 15-g (NDC 0085-0370-01) and 45-g (NDC 0085-0370-02) tubes; boxes of one.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
ELOCON® brand of M-FACT ointment, Ointment 0.1%, For Dermatologic Use Only. Not for Ophthalmic Use. SP Schering Corporation, Kenilworth, NJ 07033 USA. Rev. 9/18/02. FDA Rev date: 12/15/2002
M-FACT interactions
See also:
What other drugs will affect M-FACT?
Possible food and drug interactions when taking M-FACT:
No interactions have been noted.
M-FACT side effects
See also:
What are the possible side effects of M-FACT?
In controlled clinical studies involving 812 patients, the incidence of adverse reactions associated with the use of M-FACT (M-FACT ointment) was 4.8%. Reported reactions included burning, pruritus, skin atrophy, tingling/stinging, and furunculosis. Reports of rosacea associated with the use of M-FACT (M-FACT ointment) have been received. In controlled clinical studies (n=74) involving pediatric patients 2 to 12 years of age, the incidence of adverse experiences associated with the use of ELOCON Cream is approximately 7%. Reported reactions included stinging, pruritus, and furunculosis.
The following adverse reactions were reported to be possibly or probably related to treatment with M-FACT (M-FACT ointment) during a clinical study, in 5% of 63 pediatric patients 6 months to 2 years of age: decreased glucocorticoid levels, 1; an unspecified skin disorder, 1; and a bacterial skin infection, 1. The following signs of skin atrophy were also observed among 63 patients treated with M-FACT (M-FACT ointment) in a clinical study: shininess 4, telangiectasia 1, loss of elasticity 4, loss of normal skin markings 4, thinness 1. Striae and bruising were not observed in this study.
The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, and miliaria.
M-FACT contraindications
See also:
What is the most important information I should know about M-FACT?
M-FACT (M-FACT ointment) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.
Active ingredient matches for M-FACT:
Mometasone furoate in India.
| Unit description / dosage (Manufacturer) | Price, USD |
| 0.05 % x 10g | $ 0.83 |
| M-Fact 0.05% OINT / 10g | $ 0.83 |
| M-FACT oint 0.05 % x 10g (Medico HC) | $ 0.83 |
| M-Fact 0.05% OINT / 10g | $ 0.83 |
List of M-FACT substitutes (brand and generic names): | |
| Lometopan (Mexico) | |
| M-Furo (Turkey) | |
| M-LITE (India) | |
| 15g (Cutigen) | $ 1.27 |
| M-Lite Mometasone 0.1 %, Tretinoin0.025 %, Hydroquinone 2 %. CRM / 15g (Cutigen) | $ 1.27 |
| M-Lite Mometasone 0.1 %, Tretinoin0.025 %, Hydroquinone 2 %. CRM / 20g (Cutigen) | $ 1.45 |
| M-LITE cream 20g (Cutigen) | $ 1.45 |
| M-Lite Mometasone 0.1 %, Tretinoin0.025 %, Hydroquinone 2 %. CRM / 15g (Cutigen) | $ 1.27 |
| M-Lite Mometasone 0.1 %, Tretinoin0.025 %, Hydroquinone 2 %. CRM / 20g (Cutigen) | $ 1.45 |
| m-Mometasone (New Zealand) | |
| Makiren (Greece) | |
| MECLOMA-F (India) | |
| 10g (Esma) | $ 1.33 |
| Mecloma-F Mometasone furoate 0.1 % w/w, Fusidic acid 2 % w/w. CRM / 10g (Esma) | $ 1.33 |
| MECLOMA-F cream 10g (Esma) | $ 1.33 |
| Mecloma-F Mometasone furoate 0.1 % w/w, fusidic acid 2 % w/w. CRM / 10g (Esma) | $ 1.33 |
| Mefurosan (Indonesia) | |
| Mefurosan 10 g x 1's (Sanbe) | $ 6.90 |
| Melocon (Indonesia) | |
| Melocort (Bulgaria) | |
| Melomet (Malaysia) | |
| Melomet 0.1 % x 10 g x 50's | |
| Mena (Taiwan) | |
| Mena 0.1 % x 3 g | |
| Mena 0.1 % x 5 g | |
| Mena 0.1 % x 8 g | |
| Mena 0.1 % x 10 g | |
| Mena 0.1 % x 15 g | |
| Mesone (Indonesia, Oman, Tunisia) | |
| Mesone 0.1 % x 5 g (Assure (Aplomb)) | $ 2.23 |
| Mesone 0.1 % x 10 g (Assure (Aplomb)) | $ 3.97 |
| MESONE GEL 1 tube / 15 GM gel each (Assure (Aplomb)) | $ 1.30 |
| MESONE tab 4 mg x 10's (Assure (Aplomb)) | |
| Mesone NA Gel (Assure (Aplomb)) | $ 1.30 |
| Mesonta (Indonesia) | |
| MESOTOP (India) | |
| MESOTOP cream 0.1 % w/w x 15g (D.R John's Lab Pharma) | $ 1.51 |
| Metacon (India) | |
| Metacon 1mg CRM / 15g (Psycorem) | $ 1.20 |
| Metacon 1mg CRM / 5g (Psycorem) | $ 0.78 |
| 1 mg x 15g (Psycorem) | $ 1.20 |
| 1 mg x 5g (Psycorem) | $ 0.78 |
| METACON 0.1% OINTMENT 1 tube / 15 GM ointment each (Psycorem) | $ 1.20 |
| METACON OINTMENT 1 tube / 5 GM ointment each (Psycorem) | $ 1.20 |
| METACON cream 1 mg x 15g (Psycorem) | $ 1.20 |
| METACON cream 1 mg x 5g (Psycorem) | $ 0.78 |
| METACON lotion 0.1 % w/w x 15ml (Psycorem) | $ 1.02 |
| Metacon 0.1% Ointment (Psycorem) | $ 0.08 |
| Metacon NA Ointment (Psycorem) | $ 0.24 |
| Metacortil (India) | |
| METACORTIL CREAM 1 tube / 10 GM cream each (Macleods (Macphar)) | $ 1.05 |
See 1128 substitutes for M-FACT | |
References
- DailyMed. "FORMOTEROL FUMARATE; MOMETASONE FUROATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "mometasone furoate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "Mometasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for M-FACT are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking M-FACT. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
